13F-HR filed by Decheng Capital LLC
Decheng Capital LLC filed this 13F-HR for the quarter ended 2023-12-31, filed 2024-02-12, with 24 holding rows worth $357,920,713.
- Accession
- 0001104659-24-014002
- Filer
- CIK 2010850
- Filed
- 2024-02-12
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q4 2023
A holdings report, 24 entries on the cover page, a total value of $357,920,713 stated on the cover page (in dollars after the unit check, H1), rows summing to $357,920,713 with VALUE read as dollars as filed, 13F file number 028-23697. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| ALPINE IMMUNE SCIENCES INC | 02083G100 | COM | 7,083,288 | $135,007,469 | dollars as filed | |
| ZENTALIS PHARMACEUTICALS INC | 98943L107 | COMMON STOCK | 2,099,583 | $31,808,682 | dollars as filed | |
| PACIFIC BIOSCIENCES CALIF INC COM | 69404D108 | Stock | 2,940,361 | $28,844,941 | dollars as filed | |
| 10X GENOMICS INC CL A COM | 88025U109 | Stock | 359,554 | $20,120,642 | dollars as filed | |
| IMMUNOGEN INC | 45253H101 | COMMON STOCK | 659,928 | $19,566,865 | dollars as filed | |
| ARCUS BIOSCIENCES INC | 03969F109 | COM | 869,790 | $16,612,989 | dollars as filed | |
| KARUNA THERAPEUTICS INC | 48576A100 | COM | 47,000 | $14,875,970 | dollars as filed | |
| ROIVANT SCIENCES LTD | G76279101 | SHS | 1,279,700 | $14,371,031 | dollars as filed | |
| ILLUMINA INC | 452327109 | COM | 80,859 | $11,258,807 | dollars as filed | |
| ARGENX SE SPONSORED ADR | 04016X101 | ADR | 27,429 | $10,434,814 | dollars as filed | |
| ACELYRIN INC | 00445A100 | COM | 1,370,951 | $10,227,294 | dollars as filed | |
| KRYSTAL BIOTECH INC COM | 501147102 | Stock | 65,772 | $8,159,674 | dollars as filed | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 850,000 | $7,760,500 | dollars as filed | |
| LANTHEUS HLDGS INC | 516544103 | COM | 92,196 | $5,716,152 | dollars as filed | |
| TERNS PHARMACEUTICALS INC COM | 880881107 | Stock | 714,285 | $4,635,710 | dollars as filed | |
| AURA BIOSCIENCES INC | 05153U107 | COMMON STOCK | 515,555 | $4,567,817 | dollars as filed | |
| BEYONDSPRING INC | G10830100 | SHS | 4,958,143 | $4,450,329 | dollars as filed | |
| EQUILLIUM INC | 29446K106 | COM | 4,447,308 | $3,215,403 | dollars as filed | |
| ATRICURE INC | 04963C209 | COM | 46,259 | $1,650,984 | dollars as filed | |
| CUE HEALTH INC | 229790100 | COM | 8,980,909 | $1,459,398 | dollars as filed | |
| SCYNEXIS INC | 811292200 | COM NEW | 555,555 | $1,238,888 | dollars as filed | |
| WHITEHAWK THERAPEUTICS INC | 00032Q104 | CMN | 526,329 | $1,063,185 | dollars as filed | |
| PYXIS ONCOLOGY INC COMMON STOCK | 747324101 | Stock | 326,810 | $588,258 | dollars as filed | |
| GENEDX HOLDINGS CORP | 81663L200 | COM CL A | 103,604 | $284,911 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001104659-24-014002 | this filing | 2024-02-12 | acceptance time not in the bulk data set |